A Rare Case of Gemcitabine-Induced Pulmonary Hypertension
DOI:
https://doi.org/10.17140/PRRMOJ-5-139Keywords:
Cholangiocarcinoma, Gemcitabine, Pulmonary hypertensionAbstract
Context
Gemcitabine is the backbone of systemic treatment of locally advanced and metastatic intrahepatic cholangiocarcinoma. In re-cent literature, gemcitabine has been linked to various pulmonary side effects.
Case Report
We report a case of an 82-year-old male who developed acute pulmonary hypertension after receiving one cycle of gemcitabine for metastatic cholangiocarcinoma. His symptoms began with fatigue associated with shortness of breath and cough that worsened despite dose reduction. He developed new onset bilateral pulmonary effusions and an echocardiogram revealed findings consistent with pulmonary hypertension. A computed tomography (CT) angiogram was negative for pulmonary thromboembolism. Although he was promptly treated with diuretics and steroids, the patient could not tolerate any further therapy.
Conclusion
Gemcitabine-induced pulmonary hypertension is rare and can be challenging to diagnose, as it remains a diagnosis of exclusion. However, physicians should be vigilant of new pulmonary symptoms, as delayed treatment can cause significant patient morbidity and mortality.
References
Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangio-carcinoma: Systematic review and meta-analysis. JAMA Surg. 2014; 149(6): 565-574. doi: 10.1001/jamasurg.2013.5137
Chun YS, Javle M. Systemic and adjuvant therapies for in-trahepatic cholangiocarcinoma. Cancer Control. 2017; 24(3): 1073274817729241. doi: 10.1177/1073274817729241 Submit your article to this journal | https://openventio.org/submit-manuscript/ Case Report | Volume 5 | Issue 1| Saif MW et al
Fenocchio E, Depetris I, Campanella D, et al. Successful treat-ment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: A case report. BMC Cancer. 2016; 16(1): 793. doi: 10.1186/s12885-016-2833-9
Gupta N, Ahmed I, Steinberg H, Patel D, Nissel-Horowitz S, Mehrotra B. Gemcitabine-induced pulmonary toxicity: Case report and review of the literature. Am J Clin Oncol Cancer Clin Trials. 2002; 25(1): 96-100. doi: 10.1097/00000421-200202000-00021
Turco C, Jary M, Kim S, et al. Gemcitabine-induced pulmonary toxicity: A case report of pulmonary veno-occlusive disease. Clin Med Insights Oncol. 2015; 9: 75-79. doi: 10.4137/CMO.S26537
Baig J, Shokouh-Amiri M, Chan J, Chowdhery R, Danthurthy S, Venepalli NK. The spectrum of pulmonary toxicity in pancreatic cancer patients receiving gemcitabine combination chemotherapy. Case Rep Oncol. 2019; 12(2): 506-512. doi: 10.1159/000500242
Pagès PB, Derangere V, Bouchot O, et al. Acute and delayed tox-icity of gemcitabine administered during isolated lung perfusion: A preclinical dose-escalation study in pigs. Eur J Cardio-thoracic Surg. 2015; 48(2): 228-235. doi: 10.1093/ejcts/ezu441
Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and di-agnosis of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(25 Suppl): D42-D50. doi: 10.1016/j.jacc.2013.10.032
Casadei Gardini A, Aquilina M, Oboldi D, et al. Separate epi-sodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease. BMC Cancer. 2013; 13: 542. doi: 10.1186/1471- 2407-13-542
Belknap SM, Kuzel TM, Yarnold PR, et al. Clinical features and correlates of gemcitabine-associated lung injury: Findings from the RADAR project. Cancer. 2006; 106(9): 2051-2057. doi: 10.1002/cncr.21808
Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary tox-icity resulting from treatment with gemcitabine. Cancer. 1997; 80(2): 286-291. doi: 10.1002/(sici)1097-0142(19970715)80:2<286::aid-cncr17>3.0.co;2-q
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Pulmonary Research and Respiratory Medicine (PRRM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
